• For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it.
• However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients.
• Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System.

Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm to surrounding healthy tissue. While it has been around for decades, it’s been largely inaccessible for many cancer patients due to both the huge footprint of traditional proton therapy equipment and the high costs. However, some programs have recently turned their heads to proton therapy and are attempting to make it more accessible for those who can benefit from it.

For example, Stanford School of Medicine recently opened a new facility that offers proton therapy that’s more accessible than in the past. Working alongside medical tech companies, the university was able to shrink down the size and cost of the proton therapy equipment, making it easier for more people to access.

In addition to Stanford, companies such as Liora Technologies are also looking to make proton therapy a more accessible and viable treatment option for the patient population. Liora Technologies, a UK-based subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), that is pioneering the electronically controlled therapy that represents a shift in proton delivery.

The system, called the Linac for Image Guided Hadron Therapy (“LiGHT”) system, is a compact and modular platform that uses an electronically-controlled beam to minimize proton loss and speed up energy switching, to provide a more efficient treatment. The LiGHT system is also smaller in size, more affordable, and quicker to deploy than traditional proton therapy systems.

The system also complements LIXTE’s lead clinical candidate, called LB-100. LB-100 is a protein phosphatase 2A (“PP2A”) inhibitor that is designed to enhance the effectiveness of treatments like chemotherapy and immunotherapy by preventing the cancer cells from repairing themselves from the damage caused by these therapies.

Together, the pair combine to make a more effective treatment as the LB-100 makes cancer cells more vulnerable to radiation, and the LiGHT system delivers high-precision radiation only where it needs to go.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing differentiated cancer therapies. Instead of introducing standalone treatments, the company focuses on a first-in-class approach that aims to enhance the effectiveness of established cancer therapies. Specifically, LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with unmet medical need.

For more information, visit the company website at https://lixte.com 

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT 

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)and may include paid advertising.

• The company is advancing its Murdock Mountain phosphate project in Nevada with a focus on direct-application organic fertilizer.
• Rising oil and natural gas prices are increasing pressure on conventional fertilizer markets, many of which depend on fossil fuel elements and energy-intensive processing.
• Fertilizer prices have surged in 2026 amid the Middle East conflict and disruptions to shipping through the Strait of Hormuz.
• Nevada Organic Phosphate’s model centers on raw phosphate requiring simple grinding and bagging rather than energy and fossil fuel intensive chemical processing.
• The company is targeting the entire U.S. agricultural market, particularly the expanding organic and regenerative farming sectors.

The fertilizer industry, where oil and natural gas often play a central role in production, is highly sensitive to fluctuations in energy markets. Conventional urea and ammonia based nitrogen fertilizers are among the most energy-intensive to produce, relying heavily on natural gas as both a fuel and a source of hydrogen. When oil and gas markets tighten, fertilizer production costs often rise in parallel.

That dynamic has become more pronounced in 2026. Fertilizer markets have been disrupted following the conflict in the Middle East and associated shipping interruptions in the Strait of Hormuz, a corridor through which roughly one-third of global seaborne fertilizer trade moves, according to reporting by CNBC (https://ibn.fm/b5HOK). Fertilizer prices have risen sharply since the start of the conflict, with urea prices in some markets reportedly climbing from roughly $400–$490 per metric ton to approximately $700. Oxford Economics estimates urea and ammonia prices have surged by 50% and 20%, respectively, since hostilities began.

Global fertilizer supply has also tightened due to shutdowns of regional production facilities and export restrictions in China. These disruptions are raising concerns around food security and farmer input costs during key planting seasons.

Against that backdrop, Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, is positioning itself around a different model: supplying naturally occurring phosphate fertilizer which, unlike conventional synthetic alternatives, requires simple grinding and bagging. The Vancouver-based company is focused on advancing its Murdock Mountain phosphate project in northeastern Nevada, where it aims to produce raw organic phosphate fertilizer for U.S. agriculture. 

Unlike synthetic fertilizers that require substantial chemical conversion, the company intends to market phosphate material that can be mined, ground, bagged and shipped for direct field application, helping to reduce dependence upon volatile fossil fuel markets. This distinction is increasingly relevant as elevated oil and gas prices persist. 

Farmers in North America remain exposed to global fertilizer pricing despite domestic fossil fuel and fertilizer production. According to the U.S. Fertilizer Institute, around a third of nitrogen, phosphate and potash fertilizers used in the United States are imported. That leaves U.S. agriculture vulnerable when international supply chains are disrupted. Even in North America, where domestic oil production remains significant, producers may be incentivized to export supply into higher-priced global markets, contributing to tighter domestic pricing conditions.

Higher fertilizer costs can affect planting decisions, reduce margins for growers, and contribute to inflation in food prices. Moreover, for producers focused on organic agriculture, an expanding market, the challenge can be greater still, since certified organic operations require approved nutrient inputs that meet stricter regulatory standards. 

Nevada Organic Phosphate is unique in offering a way to deal with both inflationary fuel issues and the growing market for organic foods. The company intends to serve the broader U.S. market while also serving the growing North American organic food sector, which it estimates at approximately $35 billion.

Nevada Organic Phosphate’s primary asset is the Murdock Mountain phosphate target zone in Elko County, Nevada. The company has outlined an Exploration Target Mineral Inventory estimate of 10 million to 46 million tonnes for the main target area, with phosphate grades ranging from 3% to 15% P₂O₅. Additional target zones identified nearby could increase overall exploration potential materially, according to company disclosures.

NOP has continued advancing the project through drilling and fieldwork, with the company reporting in April that it remains on track for its 2026 drill program. Recent assay work has also suggested weighted average phosphate grades above 10% P₂O₅ in portions of the Upper Phosphatic Zone, alongside multi-nutrient chemistry supportive of soil-conditioning applications.

Beyond current geopolitical disruptions, Nevada Organic Phosphate may also be aligned with longer-term agricultural shifts. Farmers and policymakers are increasingly focused on regenerative agriculture, soil health, and reducing runoff from synthetic chemical fertilizers. Direct-application phosphate products fit within that broader movement toward alternative nutrient strategies.

As the company moves toward initial production, its focus on minimally processed phosphate fertilizer places it within a part of the agricultural supply chain that may draw increased investor attention should fertilizer inflation remain elevated and food security concerns continue to build.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP 

• A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead.
• One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study.
• Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline.

Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A recent analysis from Zacks Small-Cap Research provides that perspective for Soligenix (NASDAQ: SNGX), offering a detailed review of the company’s pipeline, upcoming catalysts and valuation potential while reinforcing the credibility of its development strategy.

The report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead. According to the analysis, the company is advancing its phase 3 FLASH2 clinical trial evaluating HyBryte(TM) for the treatment of cutaneous T-cell lymphoma, with an interim analysis expected in the second quarter of 2026 and topline results anticipated in the second half of the year. These milestones are significant because late-stage clinical readouts often represent transformational inflection points for biotechnology companies, particularly when they involve therapies targeting conditions with limited treatment options.

One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study. The report notes that the overall blinded aggregate response rate for patients who have completed the treatment phase continues to remain consistent with the 48% previously reported , compared to a 25% aggregate response rate that was originally used to power the study. This difference is meaningful because it suggests that the therapy may be outperforming initial expectations, which in turn increases confidence that the study could ultimately produce positive results.

The analysis further explores what this blinded response rate could imply. Based on the assumptions used in the study design, including a projected 40% response rate in the treatment arm and 10% in the placebo arm, the report indicates that a 48% blended response rate may point to substantially stronger performance in the active treatment group. While the exact breakdown remains unknown until data are unblinded, the interpretation offered in the report underscores why the interim data are viewed as encouraging.

Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline. The company is planning to initiate a phase 2 clinical trial of SGX945 for Behçet’s disease following completion of reformulation work expected in the second half of 2026. This program represents an expansion of the company’s focus on rare inflammatory diseases and reflects its broader strategy of developing therapies for conditions with unmet medical need.

The analysis also draws attention to recently published data comparing HyBryte to Valchlor in the treatment of cutaneous T-cell lymphoma. According to the report, 60% of patients treated with HyBryte achieved the defined level of treatment success compared to 20% of patients treated with Valchlor over a 12-week period. Although the study was small and not statistically powered, the findings provide additional support for the therapy’s potential efficacy and tolerability profile.

Market opportunity is another area emphasized in the report. The analysis estimates that the global market for cutaneous T-cell lymphoma treatments is approximately $250 million, noting that current treatment options are often limited by suboptimal efficacy or significant side effects. This context is important because it highlights the potential commercial relevance of a new therapy that can offer improved outcomes or a better safety profile.

Regulatory progress is also identified as a key component of Soligenix’s advancement. The report confirms that SGX945 has received orphan drug designation from the European Commission and Promising Innovative Medicine designation from the UK Medicines and Healthcare products Regulatory Agency. These designations are significant because they can provide development incentives, regulatory guidance and potential pathways to earlier patient access, particularly in rare disease settings.

From a financial perspective, the report provides a snapshot of the company’s current position and projected runway. Soligenix reported research and development expenses of $7.5 million in 2025, compared to $5.2 million in 2024, reflecting increased investment in clinical programs . The company ended 2025 with approximately $7.9 million in cash and cash equivalents, which the analysis estimates will fund operations into the fourth quarter of 2026. These figures provide important context for understanding how the company plans to support its ongoing development activities.

Valuation is another central component of the report’s conclusions. Using a probability-adjusted discounted cash flow model that incorporates potential future revenues from HyBryte, SGX302 and SGX945, the analysis assigns a valuation of $20 per share. The report notes that this valuation is dependent on continued clinical success, reinforcing the importance of upcoming trial results and regulatory milestones.

This recent Zacks report analysis presents a comprehensive view of Soligenix as a company entering a period defined by clinical catalysts, regulatory progress and pipeline expansion. By highlighting both the opportunities and the risks inherent in drug development, the report provides a balanced perspective that underscores the importance of continued execution.

For Soligenix, the significance of this type of independent analysis lies not only in the validation it can provide but also in the clarity it brings to complex scientific and financial developments. As the company moves toward key clinical readouts and continues to advance its rare disease programs, the insights outlined in the report help frame the potential impact of those milestones on both the company’s trajectory and the broader effort to develop new therapies for patients with limited treatment options.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals is building a portfolio of rare earth element (“REE”) exploration assets across Canada and the United States.
• Global REE demand is projected to triple by 2035, driven by a variety of growing defense and commercial needs, including electric vehicles, wind power, and AI semiconductor growth.
• China controls roughly 60% of global REE mining and 90% of processing, creating serious supply chain vulnerabilities for Western economies.
• North American governments are deploying over $1 billion in funding and incentives to develop domestic REE supply chains.
• Powermax’s projects in Ontario, British Columbia, and Wyoming offer promising opportunities in multiple deposit types and jurisdictions.

The rare earth elements (“REE”) market has moved from a niche segment of the mining industry to a strategic focal point for governments and investors. Against that backdrop, Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, is positioning itself as a key exploration-stage participant seeking exposure to a supply chain increasingly shaped by geopolitics and industrial demand.

REEs, a group of 17 elements used in magnets, batteries and electronics, are essential inputs for defense systems, as well as electric vehicles, wind turbines, and semiconductors, the latter growing due to increased AI demand. Their role in these sectors has turned them into a critical link between energy transition policies and advanced manufacturing.

Industry forecasts suggest that global REE demand could rise from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035. That trajectory is largely tied to accelerating electric vehicle adoption and expansion in renewable energy infrastructure. Market data compiled by industry analysts indicates the global REE market was valued at about $3.95 billion in 2024 and is expected to reach $6.3 billion by 2030, implying an annual growth rate near 8.6%.

At the same time, supply remains highly concentrated. China accounts for roughly 60% of global REE production and close to 90% of processing capacity. That imbalance has prompted policy responses in North America and Europe, where governments are seeking to reduce reliance on Chinese supply chains.

Recent measures include export controls from China and countermeasures from the United States, including funding initiatives and minimum pricing mechanisms aimed at encouraging domestic production. Canada has also updated its Critical Minerals List in 2024, placing REEs among its priority resources, while bilateral agreements such as the Energy Resource Governance Initiative are designed to align supply chain development across allied nations.

Eligibility for such programs could provide non-dilutive funding opportunities for exploration companies operating in these jurisdictions. At the same time, regulatory changes are tightening supply chains. For example, U.S. Department of Defense rules set to take effect in 2027 will restrict sourcing of certain rare earth magnets from countries including China and Russia, potentially reshaping procurement strategies.

Powermax’s approach reflects a portfolio model rather than a single-asset bet. The company holds interests in several REE exploration projects across North America, including the Atikokan project in Ontario, the Cameron project in British Columbia, and the Ogden Bear Lodge project in Wyoming. It has also outlined exploration plans for the Pinard project in northern Ontario. This geographic spread offers exposure to multiple geological settings and regulatory regimes, while also aligning with jurisdictions considered supportive of mining development.

The Atikokan REE project in northwestern Ontario represents one of the company’s more data-rich assets. Geochemical analysis from the Ontario Geological Survey, based on a dataset of more than 48,000 samples, identified several REE anomalies in the 99th percentile. Notably, multiple samples exceeding 500 parts per million of total rare earth elements were concentrated within the White Otter target area. These anomalies are supported by additional indicators, including radiometric and magnetic data, as well as the presence of pathfinder elements such as niobium, yttrium and zirconium.

The geological interpretation points toward REE-rich pegmatite systems associated with the White Otter Batholith. The distribution of anomalies across a broad area suggests district-scale potential, though the project remains at an early exploration stage.

In British Columbia, the Cameron REE project has undergone more recent fieldwork. Exploration activities conducted in 2023 included geological mapping, geochemical sampling and airborne geophysical surveys. Rock samples returned total REE values ranging from 12.46 parts per million to 1,426.83 ppm, with cerium emerging as the dominant element.

The identification of multiple areas of interest through geophysical surveys has led to the delineation of potential drill targets. Infrastructure access is relatively favorable, with proximity to highways and established mining communities in the Kamloops region. While the grades observed in early sampling vary widely, the presence of REE mineralization across multiple zones provides a basis for further exploration.

Powermax’s Ogden Bear Lodge project in Wyoming offers a different type of strategic positioning. The property borders the Bear Lodge Critical Rare Earth Project being advanced by Rare Element Resources, which has received significant financial backing, including more than $24 million from the U.S. Department of Energy and a potential $553 million financing package from the Export-Import Bank of the United States.

That adjacent development has already attracted over $170 million in investment and includes ongoing work on REE processing capabilities. For Powermax, proximity to a project with federal funding and established exploration data may reduce geological uncertainty while increasing the potential relevance of its own land position.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, continues with the development of its Montauban property.
• Despite expected volatility, gold prices remain stellar, approximately twice as high as two years ago.
• Initial findings at the company’s Montauban project revealed deep and expanding mineralized corridor, over 2 kilometers of strike length.

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, continues moving forward with operations, even with expected volatility from unpredictable geopolitical events. Underlying debt and economic uncertainties are seen as long-term drivers of gold and silver prices, and show no signs of abating. 

“Gold’s push above $4,800 reflects a recalibration of risk, rather than a full regime shift,” noted Ahmad Assiri, a strategist at Pepperstone Group Ltd. “The move higher suggests markets are now pricing in a lower probability of prolonged disruption while still retaining a meaningful discount versus the pre-Iran setup,” he added (https://ibn.fm/qIJJp).

ESGold remains optimistic that gold’s stellar price will continue, given ongoing world debt and political pressures. Even with volatility, the price of gold is holding approximately twice as high as it was two years ago. As a result, ESGold is doubling down on the development of its Montauban Gold-Silver Project in Québec. In March, the company closed a C$7.2 million offering that involved the sale of 10,683,000 units at C$0.68 per unit. Proceeds from the offering being directed toward advancing the Montauban project, as well as general working capital and corporate purposes.

“This next phase marks an important step in defining the full scale of Montauban,” noted Gordon Robb, ESGold’s CEO (https://ibn.fm/iM6Ju).

The company is already undertaking a 70-square-kilometer district-scale Ambient Noise Topography (“ANT”) survey at the Montauban project. This marks the second phase of the survey, building on initial findings that revealed a deep and expanding mineralized corridor extending to approximately 900 meters and over at least 2 kilometers of strike length. Once finalized, the survey will help define high-priority drill targets for future exploration while further assessing the size, shape, and continuity of mineralized anomalies on the property.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid advertising.

• The importance of magnet rare earths such as neodymium, praseodymium, dysprosium and terbium continues to grow as global electrification trends accelerate.
• Canamera Energy Metals is executing a strategy that goes beyond single-asset exploration.
• Canamera has initiated a 10-hole due diligence drilling program at Patos as it evaluates the acquisition of what would become its third ionic clay rare earth project in Brazil.

The race to secure reliable supplies of magnet rare earth elements is accelerating as global demand rises across electric vehicles, renewable energy systems and advanced electronics, prompting companies to rethink where and how these critical materials are sourced. With this in mind, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is positioning itself as a builder of a scalable rare earth platform in Brazil, with recent developments pointing to a deliberate strategy of consolidation and expansion across multiple ionic clay projects.

The importance of magnet rare earths such as neodymium, praseodymium, dysprosium and terbium continues to grow as global electrification trends accelerate. These elements are essential components in permanent magnets used in electric motors, wind turbines and a wide range of high-performance technologies. Demand for critical minerals, including rare earth elements, is expected to increase significantly as clean-energy deployment expands, with magnet materials playing a central role in enabling that transition. This rising demand has heightened concerns around supply concentration, as China continues to dominate both production and processing.

As a result, attention is increasingly shifting toward alternative jurisdictions that can help diversify supply chains. Brazil has emerged as one of the most promising regions in this regard, due to its favorable geology and the presence of ionic clay deposits similar to those historically mined in southern China. These deposits are particularly attractive because they can often be processed using simpler and lower-cost extraction methods compared with hard rock rare earth projects. Recent reports note that parts of Brazil’s rare earth resources are hosted in ionic clays, which are considered easier and more economical to develop than conventional deposits.

Within this evolving landscape, Canamera Energy Metals is executing a strategy that goes beyond single-asset exploration. The company is working to assemble a portfolio of ionic clay rare earth projects that can function collectively as a regional platform. This approach reflects a broader industry trend in which companies seek to build scale, optionality and long-term value through the consolidation of multiple prospective assets within a favorable jurisdiction.

The company’s activities in Brazil illustrate this platform-building strategy in action. Earlier work at its Turvolândia project confirmed ionic clay mineralization across a significant area, demonstrating that the company can identify and advance this style of deposit. Building on that foundation, Canamera is now evaluating additional projects that could expand its footprint and enhance the overall scale of its Brazilian operations.

The recently announced Patos project represents a key step in this process. According to the company, Canamera has initiated a 10-hole due diligence drilling program at Patos as it evaluates the acquisition of what would become its third ionic clay rare earth project in Brazil. The purpose of the program is to confirm the presence, grade and continuity of rare earth mineralization, providing the technical data needed to support a potential acquisition decision.

The significance of this development lies not only in the addition of another asset, but in what it suggests about the company’s broader strategy. By systematically identifying, evaluating and potentially acquiring multiple ionic clay projects, Canamera is working to establish a cohesive portfolio that could benefit from shared infrastructure, geological knowledge and operational efficiencies. This type of consolidation strategy can be particularly valuable in the rare earth sector, where scale and consistency of supply are important considerations for downstream customers and strategic partners.

Patos also serves as a form of proof of concept for the company’s expansion model. The progression from initial exploration to multiproject evaluation indicates that Canamera is applying a repeatable approach to asset selection and development. If successful, this strategy could position the company as a notable participant in Brazil’s emerging rare earth sector, rather than as a single-project explorer.

At the same time, the company’s focus on ionic clay deposits aligns well with current market dynamics. These deposits are not only easier to process but are also a primary source of heavy rare earth elements, which are often in shorter supply and command higher value. As global demand for these materials continues to grow, projects that can deliver them efficiently may become increasingly important.

The broader implication is that Brazil’s role in the global rare earth supply chain may expand in the coming years, particularly as exploration activity increases and more projects move toward development. Companies that establish a strong early presence and build diversified asset bases could be well positioned to benefit from this shift.

For Canamera Energy Metals, the ongoing work at Patos and its evaluation as a third ionic clay project represents more than simply incremental growth. It reflects a strategic effort to build a scalable rare earth platform in a region that is gaining recognition as a new hub for these critical materials. As the company continues to advance its portfolio, its multi-project approach may offer a pathway to greater scale, resilience and long-term value in an increasingly competitive and strategically important sector.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

• Trilogy Metals’ joint venture, Ambler Metals, is taking steps to advance permitting, drilling, and feasibility milestones at its Arctic and Bornite projects in Alaska.
• Growing U.S. support for domestic critical mineral development is strengthening Trilogy’s position as a high-grade, multi-metal asset with increasing strategic value.

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) is entering a critical phase in its evolution, with President and CEO Tony Giardini listing out a couple of near-term catalysts that could significantly progress the company’s flagship assets in Alaska’s Ambler Mining District. In a recent interview, Giardini emphasized that 2026 will be defined by execution, as Trilogy moves to derisk its projects while positioning itself within a tightening global supply landscape for critical minerals (ibn.fm/0mtgC).

An important milestone on the horizon is the expected closing of a previously announced $35.6 million U.S. government-backed investment, which is set to strengthen the company’s balance sheet while leveraging continued federal support for domestic resource development. The investment aligns with broader policy momentum aimed at securing reliable supply chains for critical minerals such as zinc, copper, and other base and precious metals essential to infrastructure, electrification, and defense applications. 

Operationally, the company’s joint venture, Ambler Metals, is advancing permitting efforts for its Arctic project, while preparing for a 2026 field program to further define and expand the resource base in support of  an upcoming feasibility study at the joint venture level. According to Giardini, continued drilling results, engineering studies, and resource updates will play a critical role in advancing the project toward development readiness.

The Arctic deposit itself remains a vital asset, hosting about 50 million tonnes grading about 5.6% copper equivalent, positioning it as one of the highest-grade undeveloped copper projects globally. This high-grade profile, combined with a diversified metal mix that includes silver, zinc, gold and lead, positions Trilogy to serve multiple industrial value chains, from advanced manufacturing to energy infrastructure.

Also important is the long-term potential of the Bornite project, which, along with Arctic, provides Trilogy a rare blend of grade and scale within a single district. As noted by Giardini, the presence of two premium-quality deposits differentiates the company from many of its peers and offers optionality as global demand for copper and associated metals increases.

The broader market context further improves Trilogy’s investment case. Recent consolidation in the sector, including the acquisition of Arizona Sonoran by Hudbay, has reduced the number of advanced domestic copper development projects. This dynamic introduces a degree of scarcity value, especially for high-grade assets located within America.

Looking ahead, Giardini underscored that 2026 will be focused not only on technical progress but also on ensuring that the company’s story is well communicated to the market. With a federal stamp of approval through the government’s strategic investment in Trilogy, that enhances the district’s visibility and credibility, the company appears well positioned to move toward long-term value creation.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at https://ibn.fm/TMQ

• Safe Pro Group, a developer of security and defense solutions, has appointed decorated SOCOM Joint Acquisition Task Force Commander Jarret Mathews as Chief Operating Officer.
• Mathews brings more than 25 years of experience to the table, with expertise in operational leadership, defense acquisition, and advanced technology integration.
• Safe Pro Group was also awarded a support contract for their AI Edge Processing solution contract awarded earlier by the U.S. Government.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-enabled defense, security, and situational awareness solutions, recently announced the appointment of Colonel (Ret.) Jarret Mathews as Chief Operating Officer (“COO”) (https://ibn.fm/7QDQk). 

Before he retired from the U.S. Army, Colonel Mathews served as Director of the Joint Acquisitions Task Force within the U.S. Army Special Operations Command (“SOCOM”). In this role, he led the development and integration of AI and machine learning technologies and drove acquisition reform initiatives to speed up SOCOM’s innovation pipeline.

In total, he brings over 25 years of defense acquisition expertise, operational leadership, and advanced technology integration experience to Safe Pro, as it aims to accelerate the government contract capture strategy for its AI and computer vision solutions, drone-based services, and ballistic protection products.

The appointment is a part of Safe Pro’s strategy to deepen relationships within the defense sector and secure contracts and revenue.

Speaking about the appointment, Safe Pro Group Chairman and CEO, Dan Erdberg, said that “Over the past six months as a special advisor, Jarret has demonstrated exceptional leadership, enhanced our operational execution capabilities, and brought unique insights into the evolving procurement needs of the U.S. military. His appointment as COO reflects our confidence in both his expertise and in the significant contract opportunities we see ahead.”

In addition to this appointment, Safe Pro also received a new contract modification to provide support for the AI Edge Processing solution they recently delivered to the U.S. Government (https://ibn.fm/4yssV).

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that delivers advanced AI-powered security and defense solutions to customers in the homeland security, defense, humanitarian, and law enforcement industries. At the heart of Safe Pro’s mission is patented computer vision software technology, which helps rapidly detect small objects in drone-based photos and videos to make field operations safer and more efficient.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)and may include paid advertising.

• Junior Canadian near-term gold producer LaFleur Minerals is positioned to restart operations at its Beacon Gold Mill in Canada’s prolific Abitibi Greenstone Belt
• LaFleur will use a bulk sample remaining from the previous company’s operations at its nearby Swanson Gold Project to produce its first gold pour, with the aim to increase the daily processing capacity of the mill over the next year
• Gold’s spot price has roughly doubled since January of last year and, although the price has fluctuated in response to geopolitical pressures during the past month, the price has remained near record levels
• LaFleur’s strategy is based on the low CapEx and low complexity of its mine-to-mill project, using a low base case scenario in its recent positive PEA that outlines robust economics, thanks to opportune key asset acquisitions, funding efforts, and the project’s strategic location in an established mining region

Near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is positioned to begin gold production during the current quarter at its key asset, Beacon Gold Mill, in the prolific Abitibi Belt of Québec, anticipating a quick entry into the market that takes advantage of pricing pressures keeping the precious metal in record territory. 

Gold has enjoyed a massive surge in spot value since the beginning of the current U.S. administration, almost doubling since January 2025 despite global political variables. Recent market fluctuations have brought gold back from its record peak last month, but it continues to hover near that high level and experienced a bit of a rebound in early April as the United States and Israel agreed to a temporary ceasefire in their war with Iran, the most recent of the geopolitical concerns (https://ibn.fm/MukA6). 

LaFleur CEO and Director Paul Ténière told investors during a March 24 webinar that the company’s profitability forecast is built on a base case price closer to where gold traded in January 2025, meaning that even with recent fluctuations the precious metal’s price remains far above the level LaFleur has developed as the foundation for its positive income strategy. 

“With this being such a low-cost operation, we don’t anticipate any issues there at all,” Ténière said during the web presentation. “We’re looking at an all-in sustaining cost of just under $1,600 an ounce. Which, again, is very impressive. And, again, this is at a base case of $2,750. Our technical report will be looking at a sensitivity of up-to-$5,000 gold. … We can certainly be running (our Swanson gold project) for the next few years and be a very cost-effective and profitable operation.”

LaFleur’s Swanson Gold Project covers 192 square kilometers near Val d’Or, Quebec, an established jurisdiction and mining camp for labor and resources that sustain the varied exploration efforts throughout the Abitibi region in eastern Canada. The company is working with railroad officials to establish a spur from the rail line running across the property directly to its Beacon Gold Mill, which would simplify transport and enhance economics. 

“We can actually, if we needed to, bring in material from anywhere within Quebec, and even Ontario, all the way to Red Lake if we needed to,” Ténière said. “So we’ve had many inquiries about toll milling, custom milling. Our main focus is to actually, because Swanson is in the short-term going to be in production, is to of course focus on that. But with the upgrades we’ve been discussing we could look at multiple options.”

The plans to restart gold production at Beacon Gold Mill hinge on completing the recommissioning and rehabilitation process under way since LaFleur obtained the mill two years ago in the former owner’s bankruptcy sale, with previously announced mill recommissioning work approximately halfway there and progressing every day.

“We were very lucky to get this mill at a very low cost,” Ténière said. “This was at a time when gold prices were obviously much lower. But this was a mill that was in excellent condition. When we acquired it it was as if the crew had left the day before. … We’re now over 50% of the way (toward restarting production) and staying within the original budget of almost $4 million for that.”

Beacon Gold Mill will initially be able to process material at 750 metric tons per day (“TPD”), using approximately 100,000 metric tons from a bulk sample to establish the company’s first gold pour. Following a staged approach to increasing production, the company will spend the first year building up to 1,000 TPD and then to 1,250 TPD. Its two-year target is 3,000 to 4,000 TPD, Ténière said. 

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.

• Workplace substance misuse costs U.S. employers over $81 billion annually through lost productivity, accidents, healthcare costs, and liability, with studies indicating that up to 40% of industrial workplace fatalities involve alcohol misuse.
• MindBio is introducing the world’s first AI-powered voice analytics system to detect drug and alcohol impairment in real time, initially targeting the South American mining sector, where heavy machinery and remote operations make safety monitoring critical.
• Such advanced screening technology has relevance to a global market spanning a range of safety-sensitive industries, including mining, construction, and aviation.

Industrial employers across the world face a persistent challenge: ensuring workers operating heavy machinery or performing safety-critical tasks are not impaired by drugs or alcohol. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is addressing that problem with a technology more commonly associated with consumer devices than workplace safety: artificial intelligence-driven speech analysis.

The biotechnology company, which has spent several years conducting research into intoxication detection, has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world. Instead of relying on traditional biological testing methods such as breathalyzers or laboratory samples, MindBio’s technology analyzes acoustic patterns in speech to estimate intoxication levels.

The platform is being developed for enterprise use, with the company currently preparing a hardware kiosk system that can screen workers as they enter industrial facilities. The kiosk will prompt workers to speak briefly, allowing the AI model to evaluate voice characteristics associated with intoxication.

The company’s technology analyzes more than 140 speech parameters and processes them through machine-learning models trained on more than 50 million data points. According to MindBio, early testing has shown prediction accuracy above 85% for blood alcohol concentration estimation and roughly 88% accuracy for intoxication classification.

The potential market for such systems reflects the scale of workplace substance misuse. Research published by organizations including the U.S. Department of Labor estimates that substance abuse costs American employers more than $81 billion each year, driven by lost productivity, workplace accidents, healthcare expenses and legal liabilities. (https://ibn.fm/3bv3C).

Approximately 9% of full-time workers in the United States meet the criteria for a substance use disorder each year, according to those estimates. Workers struggling with substance misuse often operate at significantly reduced efficiency. Studies cited by addiction research groups suggest impaired employees may function at around 70% of their normal capacity, creating operational delays and higher error rates.

The financial impact goes beyond productivity losses. It is estimated that each employee with a substance abuse problem can cost an employer between $8,000 and $12,000 annually in combined productivity losses, healthcare spending and accident-related expenses.

For industries dependent on safety and reliability, the risks are particularly acute. Workers who misuse drugs or alcohol are estimated to be 3.6 times more likely to be involved in workplace accidents. Alcohol alone is believed to contribute to roughly 40% of industrial workplace fatalities, underscoring the legal and financial exposure companies face when impairment goes undetected.

MindBio’s early commercial focus reflects those risks. The company is concentrating first on mining operations in South America, a sector characterized by large workforces operating heavy machinery in remote environments. In Chile, for example, data referenced by the company indicates alcohol consumption among mining workers exceeds 75%, with roughly 40% classified as problem drinkers. Such statistics illustrate why impairment screening has become a priority for mining companies operating large industrial sites.

Traditional testing systems typically rely on breathalyzers, urine testing or laboratory blood analysis. These approaches can require specialized staff, laboratory processing or waiting periods that slow down shift changes and facility entry. MindBio’s proposed kiosk system streamlines the process. Workers would simply speak into a terminal at the worksite entrance. The Edge AI device processes the voice sample locally and delivers a rapid screening result, potentially allowing companies to identify impaired workers without delaying operations. Field testing of the kiosk platform is expected to begin in the second quarter of 2026. 

The company’s approach relies on acoustic biomarkers: subtle features in speech patterns that change as alcohol or drugs affect cognitive and motor function. Machine learning models analyze these speech features, including rhythm, frequency variations and articulation changes. Because voice samples can be captured quickly through standard microphones, the system can theoretically scale across both enterprise and consumer applications. Alongside the enterprise platform, MindBio also offers a consumer application called Booze AI, which allows individuals to estimate blood alcohol concentration using a smartphone or web interface.

While mining represents an initial market, the broader opportunity may lie in other  safety-critical sectors. Construction, aviation, transportation and energy industries all face similar challenges related to impairment detection. In these environments, employers often face strict regulatory requirements regarding alcohol and drug policies.

Workplace research indicates heavy drinking rates reach 17.5% among mining workers and 16.5% among construction employees, significantly higher than many other industries. These sectors also carry high accident costs. Construction workers, for example, experience some of the highest rates of job-related injury and overdose deaths among all professions. MindBio’s technology could potentially fit within a much larger global market centered on occupational safety and regulatory compliance.

For more information, visit the company’s website at www.MindBioTherapeutics.com. 

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF